To Örebro University

oru.seÖrebro University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Expression of PD-L1, TIGIT, and CD155, and Human Papillomavirus Status in Patients with Advanced Penile Cancer
Örebro University, School of Medical Sciences. Department of Oncology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Örebro University Hospital. Örebro University, School of Medical Sciences. Department of Urology.ORCID iD: 0000-0002-4738-9223
Regional Cancer Centre Mid Sweden, Uppsala, Sweden.
Örebro University, School of Health Sciences. Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden.ORCID iD: 0000-0001-9992-266x
Show others and affiliations
2025 (English)In: European Urology Open Science, ISSN 2666-1691, E-ISSN 2666-1683, Vol. 79, p. 102-110Article in journal (Refereed) Published
Abstract [en]

BACKGROUND AND OBJECTIVE: To improve treatment for patients with penile cancer, there is a need for prognostic and treatment predictive biomarkers. The objective of this study was to examine the expression of checkpoint proteins (programmed cell death ligand 1 [PD-L1], T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain [TIGIT], and cluster of differentiation 155 [CD155]) and human papillomavirus (HPV) status in primary tumors of penile cancer patients with indication for perioperative oncological treatment. As a secondary aim, we evaluated the associations between these biomarkers and penile cancer-specific survival.

METHODS: Fifty-two patients who underwent surgical treatment during 2009-2018 were included. HPV status was determined by polymerase chain reaction, and tissue microarray sections from primary tumors were subjected to immunohistochemistry to evaluate the expression of PD-L1, TIGIT, and CD155.

KEY FINDINGS AND LIMITATIONS: PD-L1, TIGIT, and CD155 were expressed widely. Specifically, 75% of patients had PD-L1-positive tumors, 80% had TIGIT-positive tumors, and 98% had CD155-positive tumors. Additionally, 47% of patients had HPV-positive tumors. Patients with HPV-positive tumors had better survival than those with HPV-negative tumors. Patients with indication for perioperative oncological therapy who received such treatment and whose tumors exhibited low PD-L1 expression demonstrated better survival than those with higher PD-L1 expression levels. The main limitations of this study include the small number of patients, retrospective design, and use of tissue microarrays rather than whole tissue sections.

CONCLUSIONS AND CLINICAL IMPLICATIONS: We found high expressions of the investigated checkpoint proteins, suggesting an immunosuppressed tumor microenvironment in patients with advanced penile cancer. These findings imply that checkpoint proteins could serve as prognostic and treatment predictive biomarkers. Patients with HPV-positive tumors had better prognosis.

PATIENT SUMMARY: In this report, we investigated tumor tissue from patients with penile cancer and identified a high prevalence of proteins that play an important role in the immune system's defense against cancer. The findings suggest that these proteins can be important in understanding and developing treatments for patients with lymph node metastasized penile cancer.

Place, publisher, year, edition, pages
Elsevier, 2025. Vol. 79, p. 102-110
Keywords [en]
CD155, Chemotherapy, Human papillomavirus, PD-L1, Penile cancer, Radiotherapy, TIGIT, Tumor microenvironment
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-122986DOI: 10.1016/j.euros.2025.07.012ISI: 001584598200001PubMedID: 40822998OAI: oai:DiVA.org:oru-122986DiVA, id: diva2:1991583
Funder
Region Örebro County
Note

Funding Agencies:

Funding for this work has been obtained through the Agreement concerning research and education of doctors (ALF) from Region Örebro County and from the Research Committee of Region Örebro County, and the Steering Group for the National Penile cancer Register of Sweden. 

Available from: 2025-08-25 Created: 2025-08-25 Last updated: 2025-10-14Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records

Ulvskog, E.Kirrander, PeterLillsunde-Larsson, GabriellaDorofte, LuizaDavidsson, Sabina

Search in DiVA

By author/editor
Ulvskog, E.Kirrander, PeterLillsunde-Larsson, GabriellaDorofte, LuizaDavidsson, Sabina
By organisation
School of Medical SciencesÖrebro University HospitalSchool of Health Sciences
In the same journal
European Urology Open Science
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 28 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf